



DRIVE ANNUAL FORUM

8 June 2022

Brussels Pullman Midi hotel & Stream online via Zoom

SESSION 1- Public Roundtable (organized by ACUMEN)

The benefits of Public-Private Partnership generated RWE for vaccine monitoring - Lessons from DRIVE

Registration link:

https://us02web.zoom.us/webinar/register/WN_SubVi_cORUCgkCVvQpUFMQ

Topic	Speaker	Time
Introductory Remarks	Javier Diez Domingo (<i>FISABIO- DRIVE Coordinator</i>) and Cédric Mahé (<i>Sanofi – DRIVE EFPIA lead</i>)	14.00-14.10
Opening statements	<ul style="list-style-type: none"> • Wolfgang Philipp Acting Director of the DG Health Emergency Preparedness and Response Authority (HERA) • Marco Cavaleri Head of Biological Health Threats and Vaccines Strategy, EMA • Hanna Nohynek Chief Physician, Deputy Head Unit Infectious Disease Control & Vaccines, National Institute for Health and Welfare, THL, Finland • Sibilia Quilici Executive Director, Vaccines Europe 	14.10-14.35
Discussion	Moderated by: Susan Saville Interventions by: <ul style="list-style-type: none"> • Pierre Meulien (Executive Director of the Innovative Medicines Initiative (IMI)) • Harish Nair (The University of Edinburgh, RESCEU-PROMISE Coordinator, Co-Director Centre for Global Health) 	14.35-15.20
Q&A	<ul style="list-style-type: none"> • Bruno Lina (UCBL, Chair of <i>Scientific Committees of the Global Influenza and RSV Initiative and the Global Influenza Hospital Surveillance Network</i>) 	15.20-15.30
Coffee break		15.30-16:00



SESSION 2 – Public poster session and experience sharing

Feasibility of generating brand-specific IVE over 5 seasons in Europe for informed decision making: key assets and challenges – Lessons from DRIVE

Zoom Link for connection:

https://gene-electra.zoom.us/meeting/register/tZcvfuGqqDovHdEzI9wV4m93ee_2pGULRCJK

Topic	Speakers	Time
<i>Introduction (plenary session):</i> DRIVE key assets and legacy for future collaborative Real World Evidence platform	Antonio Carmona (FISABIO) Anke Stuurman (P95), Laurence Torcel-Pagnon (Sanofi) <i>on behalf of DRIVE consortium</i>	16.00-16:10
Poster presentation for online attendees	Poster presenters	16:10-16:45
Poster session: <i>DRIVE Collaborative framework and Governance boundaries</i> <i>The evolution of DRIVE's study platform and site network</i> <i>The site's perspective: Experience in participating in IVE collaborative studies</i> <i>Is publicly accessible data on influenza vaccine availability in the EU able to inform (brand-specific) influenza vaccine effectiveness studies?</i> <i>Pragmatic approach to account for bias and confounding in Test-Negative Design influenza vaccine effectiveness studies</i> <i>Interactions with regulatory authorities to address the EMA brand-specific requirement on seasonal influenza vaccines</i> <i>How to communicate influenza vaccine effectiveness by brand as outputs from a public private partnership</i>	Laurence Torcel-Pagnon (Sanofi) and Hanna Nohynek (THL) Antonio Carmona (FISABIO) and Alexandre Descamps (INSERM) Stefano Mosca and CIRI-IT colleagues (CIRI-IT) Mendel Haag (Seqirus) and Caterina Rizzo (University of Pisa) Anke Stuurman (P95) and Jos Nauta (Abbott) Pieter Neels (IABS-EU) and H�elene Bricout (Sanofi) J�ulia Garc�ia-Bayarri (FISABIO) and Riika Rossi (THL)	16:50-17:40
<i>Closure (plenary session):</i> COVIDRIVE: Leveraging influenza platform to tackle COVID-19 pandemic. First COVID-19 vaccine effectiveness study.	Antonio Carmona (FISABIO), Kaatje Bollaerts (P95), Laurence Torcel-Pagnon (Sanofi) <i>on behalf of COVIDRIVE consortium</i>	17:40-18:00